Vol. 2 No. 2 (2010): New Drugs and Hemopoietic Stem Cell Transplantation in Oncohematological Diseases of the Elderly

Perspectives

TREATMENT OF CANCER IN THE OLDER AGED PERSON

Lodovico Balducci

e2010029

https://doi.org/10.4084/mjhid.2010.029

1126

PDF: 804

HTML: 3343
- PDF
- HTML

Review Articles

ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Mohamed L. Sorror, Rainer F. Storb

e2010015

https://doi.org/10.4084/mjhid.2010.015

944

PDF: 604

HTML: 2198
- PDF
- HTML
CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH

Lisa Pieri, Paola Guglielmelli, Alessandro Maria Vannucchi

e2010017

https://doi.org/10.4084/mjhid.2010.017

1599

PDF: 697

HTML: 2326
- PDF
- HTML
OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE

Francesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, Miriam Isola, Maria Teresa Van Lint, Anna Paola Iori, Paolo Di Bartolomeo, Maurizio Musso, Pietro Pioltelli, Giuseppe Visani, Pasquale Iacopino, Renato Fanin, Alberto Bosi

e2010010

https://doi.org/10.4084/mjhid.2010.010

1447

PDF: 743

HTML: 748
- PDF
- HTML
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

Tadeusz Robak

e2010011

https://doi.org/10.4084/mjhid.2010.011

1611

PDF: 622

HTML: 2412
- PDF
- HTML
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA

Luca Laurenti, Michela Tarnani, Patrizia Chiusolo, Federica Sorà, Simona Sica

e2010026

https://doi.org/10.4084/mjhid.2010.026

1311

PDF: 728

HTML: 930
- PDF
- HTML
THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson

e2010009

https://doi.org/10.4084/mjhid.2010.009

1023

PDF: 676

HTML: 598
- PDF
- HTML
"ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro

e2010013

https://doi.org/10.4084/mjhid.2010.013

1326

PDF: 639

HTML: 1493
- PDF
- HTML
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

e2010021

https://doi.org/10.4084/mjhid.2010.021

1859

PDF: 702

HTML: 677
- PDF
- HTML
ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME

Teresa L Field, Claudio Anasetti

e2010019

https://doi.org/10.4084/mjhid.2010.019

1257

PDF: 564

HTML: 1172
- PDF
- HTML

How I Treat

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TREATMENT OF CHRONIC LYMPHOCITIC LEUKEMIA : WHY AND WHEN ?

Maria L. Delioukina, Stephen J. Forman

e2010018

https://doi.org/10.4084/mjhid.2010.018

1188

PDF: 764

HTML: 524
- PDF
- HTML

Original Articles

POOR HEMOPOIETIC STEM CELL MOBILIZERS IN MULTIPLE MYELOMA : A SINGLE INSTITUTION EXPERIENCE

Guillermo Jose Ruiz-Delgado, Avril Lopez-Otero, Ana Hernandez-Arizpe, Aura Ramirez-Medina, Guillermo Jose Ruiz-Argüelles

e2010016

https://doi.org/10.4084/mjhid.2010.016

1129

PDF: 710

HTML: 567
- PDF
- HTML
CLINICAL ANALYSIS AND OPTIMIZATION OF POST-REMISSION THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH MINIMAL RESIDUAL DISEASE AS DETERMINED BY FLOW CYTOMETRY

Daichi Inoue, Hayato Maruoka, Takayuki Takahashi

e2010020

https://doi.org/10.4084/mjhid.2010.020

1205

PDF: 734

HTML: 1152
- PDF
- HTML

Case Reports

PHENYTOIN-ASSOCIATED LYMPHOADENOPATHY MIMICKING A PERIPHERAL T-CELL LYMPHOMA

Mark E. Johns, Lynn C. Moscinski, Lubomir Sokol

e2010028

https://doi.org/10.4084/mjhid.2010.028

1202

PDF: 777

HTML: 5484
- PDF
- HTML

Letters to the Editor

Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain

e2010012

https://doi.org/10.4084/mjhid.2010.012

1001

PDF: 667

HTML: 330
- PDF
- HTML

Current Issue

Perspectives

TREATMENT OF CANCER IN THE OLDER AGED PERSON

Review Articles

ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE

APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA

THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

"ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME

How I Treat

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TREATMENT OF CHRONIC LYMPHOCITIC LEUKEMIA : WHY AND WHEN ?

Original Articles

POOR HEMOPOIETIC STEM CELL MOBILIZERS IN MULTIPLE MYELOMA : A SINGLE INSTITUTION EXPERIENCE

CLINICAL ANALYSIS AND OPTIMIZATION OF POST-REMISSION THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH MINIMAL RESIDUAL DISEASE AS DETERMINED BY FLOW CYTOMETRY

Case Reports

PHENYTOIN-ASSOCIATED LYMPHOADENOPATHY MIMICKING A PERIPHERAL T-CELL LYMPHOMA

Letters to the Editor

Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

Links

Information

Indexing

PubMed

MJHID CiteScore by Scopus

Clarivate Analytics

AskBisht

Facebook

MJHID in EuroPub Database

CLL UpDate

Keywords